AVAI BIO, INC.
No SEC Form 4 filings for $AVAI in the last 30 days.
See all $AVAI insider activity →Avaí Bio (AVAI) completed viral and contaminant testing for its GMP Master Cell Bank, confirming it is free of over 30 viruses and other agents. The company, along with Austrianova, is developing a-Klotho-producing cell therapies through their joint venture, Klothonova. The milestone supports further development of the anti-aging therapy. AVAI stock is currently at $0.14, up 21.74%.
AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AVAI (AVAI BIO, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Positive milestone reduces regulatory risk and supports progression of anti‑aging cell therapy program.
Potential advancement in encapsulated beta cell therapy could boost AVAI's pipeline and attract investor interest.
AlphAI scores every news story that mentions AVAI with an AI model for sentiment and relevance, and aggregates insider trades from AVAI BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Avaí Bio (AVAI) completed viral and contaminant testing for its GMP Master Cell Bank, confirming it is free of over 30 viruses and other agents. The company, along with Austrianova, is developing a-Klotho-producing cell therapies through their joint venture, Klothonova. The milestone supports further development of the anti-aging therapy. AVAI stock is currently at $0.14, up 21.74%.
2 min readAVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.
3 min read
